Age Threshold of 50 for New Zoster Vaccine Not Cost-Effective: Study Age Threshold of 50 for New Zoster Vaccine Not Cost-Effective: Study

The new Advisory Committee on Immunization Practices (ACIP) guideline that recommends the new recombinant adjuvanted zoster subunit vaccine (RZV) over the live attenuated zoster vaccine (ZVL) and lowers the vaccination age to 50 years is not cost-effective, according to a new analysis.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news